trending Market Intelligence /marketintelligence/en/news-insights/trending/JfC49XYT1Ii-jxpfpdfmfg2 content esgSubNav
In This List

United Therapeutics' Trevyent accepted for US FDA review

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


United Therapeutics' Trevyent accepted for US FDA review

United Therapeutics Corp.'s experimental drug-device combination to treat pulmonary arterial hypertension has been accepted for review by the U.S. Food and Drug Administration.

The regulatory body is expected to give its decision on the Silver Spring, Md.-based company's application by April 27, 2020.

Pulmonary arterial hypertension is a rare type of high blood pressure that affects arteries in the lungs and the right side of the heart. It is characterized by dizziness and chest pressure.

Trevyent is being developed as a combination of treprostinil and the PatchPump technology, to be administered via injections.

Both Trevyent and the PatchPump technology are propriety products of SteadyMed Ltd., a subsidiary of United Therapeutics.